Molecular Diagnostic Pricing Database

All prices for Abbott, Cepheid and Roche are indicative; small variations are possible based on the individual components in any given order.

Abbott mPima pricing: The exact price point within the range provided will depend on the combination of existing instruments (which were purchased) and new instruments (which will be placed), as well as whether the existing instruments are under warranty.

Instrument placement assumes utilizing in-country molecular infrastructure and placing additional equipment only if volumes justify doing so.

Other incoterms are possible at additional cost, please contact Cepheid directly.

MTB/RIF (GX4) is being discontinued

Applicable only to GX XVI platforms.

S&M would be included for all GX XVI platforms placed in the price per test.

Cepheid’s pricing for all GX assays indicated above is prepaid (payment made in full before goods are shipped) and when procured directly from Cepheid. Additional cost would be added when incoterm is different from EXW and/or when goods are procured through a local distributor.

If the 30,000 test/instrument annual average cannot be met, Hologic has a separate pricing model that may be applicable for certain eligible countries.

This is a ceiling price associated with the volume commitment outlined above; lower prices may be accessed on a country-by-country basis.

Different prices may apply for special projects/grants, please contact Roche directly.

Abbott is in the process of revising the volume tiers and establishing global base prices with committed volumes for HIV, HBV and HCV tests. Please confirm updates with supplier.

Each GX XVI placement requires an annual purchase of 10,000 tests (of any corresponding assay listed except SARS-CoV-2) spread across all GeneXpert systems in the participating country.

Specific incoterm to be decided based on negotiation.

Other countries can be added based on instrument launch.

Other countries can be added on an ad-hoc basis.

Special all-inclusive pricing for Aptima HPV is enabled through a 1,000,000 annual test volume commitment under the Global Health Supply Chain – Procurement and Supply Management Project (GHSC-PSM). 

Only compatible with 10-color devices (R2 model). Other assays can be run on either R1 (6-color) or R2 (10-color) devices. 

6-color devices (R1 model) have been discontinued, though countries can continue to receive technical support and replacement parts. A trade in program to switch R1 devices for R2 devices is available, details linked.

This package is available from the 31st of January until the 31st of December 2023. A formal PO will need to be placed within these dates to avail of the offer. Details linked.

20 Truenat MTB/RIF tests free with purchase of 100 Truenat MTB/MTBPLUS tests purchased. In the future users will be able to select a combination of MTB/RIF and INH assays for free along with with purchase of 100 Truenat MTB/MTBPLUS tests; buyers will have the flexibility to choose the numbers of RIF and INH respectively while the total number of free tests will remain at 20%.

UNO workstation = UNODx + TrueprepAUTO + Printer + Pipette + Accessories

DUO workstation = DUODx + TrueprepAUTO + Printer + Pipette + Accessories

QUATTRO workstation = QUATTRO + 2 units TrueprepAUTO + Printer + Pipette + Accessories

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by the authorized laboratories; this product has been authorized only for the detection of nucleic acid from monkeypox virus or other non-variola orthopoxviruses, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

MTB/ RIF-INH – The Roche Global Access Program pricing model encourages reflex RIF/INH testing as per WHO Guidance. price per test for every patient is $8.90 ($7.90 + $1.00 for RIF/INH reflex)

Instrument Surcharge (Reagent Rental) is determined by the total annual volumes of all tests (HIV, HPV, MTB and HCV/HBV, COVID-19) at the country level averaged across the entire footprint; for country specific details please contact Roche directly

Service Surcharge is determined by the total annual volumes of all tests (HIV, HPV, MTB and HCV/HBV, COVID-19) at the country level averaged across the entire footprint, for country specific details please contact Roche directly.

Supply Chain Surcharge for Incoterms DAP is determined by country specific factors considering volatility around logistics costs, for country specific details please contact Roche directly